Forskning
Udskriv Udskriv
Switch language
Bispebjerg Hospital - en del af Københavns Universitetshospital
Udgivet

Risk of Adverse Pregnancy Outcome After Paternal Exposure to Methotrexate Within 90 Days Before Pregnancy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies at Delivery in Women, Partners, and Newborns

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Exposure to Selective Serotonin Reuptake Inhibitors in Early Pregnancy and the Risk of Miscarriage

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Association between maternal weight gain and birth weight

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Pharmacological but not physiological GDF15 suppresses feeding and the motivation to exercise

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Association between use of macrolides in pregnancy and risk of major birth defects: nationwide, register based cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Developing and validating COVID-19 adverse outcome risk prediction models from a bi-national European cohort of 5594 patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Male fertility before and after androgen abuse

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. How patients in Denmark acquire their medicines: overview, data sources and implications for pharmacoepidemiology

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

OBJECTIVE: To study the association between paternal exposure to methotrexate within the 90-day period before pregnancy and congenital malformations and stillbirth in the offspring.

METHODS: We conducted a nationwide register study. Our cohort consisted of all live births in Denmark between 1997 and 2011 identified from the Medical Birth Registry. Methotrexate-exposed fathers were identified from the National Prescription Registry. From the national Hospital Registry we identified paternity, live births, and stillbirths as well as discharge diagnoses on congenital malformations.

RESULTS: We identified 849,676 live births with known paternity. There were 127 live births of methotrexate-exposed fathers. Of these, four (3.2%) had major malformations compared with 28,814 (3.4%) of the unexposed. The odds ratio (OR) for major congenital malformation among exposed fathers compared with unexposed was 0.93 (95% confidence interval [CI] 0.34-2.51) and when adjusted for year of birth, maternal age, educational length, household income, and parity, the adjusted OR was 1.01 (95% CI 0.37-2.74). There were no stillbirths in the methotrexate-exposed group compared with 2,541 (0.3%) in the unexposed group and no increased risk of preterm birth (adjusted OR 1.31, 95% CI 0.66-2.59) among the children from exposed fathers.

CONCLUSION: We found no association between paternal exposure to methotrexate within 90 days before pregnancy and congenital malformations, stillbirths, or preterm birth. Available data suggest that prepregnancy paternal methotrexate exposure should not be of major concern. Multinational recommendations should be changed accordingly.

OriginalsprogEngelsk
TidsskriftObstetrics and Gynecology
Vol/bind129
Udgave nummer4
Sider (fra-til)707-714
ISSN0029-7844
DOI
StatusUdgivet - 1 apr. 2017

ID: 50109122